– ETESIAN Phase 2b study of ION449 (AZD8233) met its primary and secondary endpoints; ION449 was generally well tolerated – ION449 demonstrated potential best-in-class efficacy profile for a self-administered subcutaneous monthly dose regimen – Study findings warrant further clinical development
Biogen and Ionis Announce Topline Phase 1 Study Results of Investigational Drug in C9orf72 Amyotrophic Lateral Sclerosis
BIIB078, an investigational antisense oligonucleotide for C9orf72-associated amyotrophic lateral sclerosis (ALS), did not show clinical benefit; clinical program will be discontinued Biogen and Ionis remain committed to their decade-long pursuit of advancing ALS research and developing therapies
Ionis announces publication of positive Phase 2 data for donidalorsen in New England Journal of Medicine
Treatment with donidalorsen in Phase 2 study significantly reduced angioedema attacks by 90% and provided improvement in quality of life Published findings demonstrate favorable safety and tolerability profile of donidalorsen in Phase 2 study Donidalorsen is one of Ionis’ wholly owned medicines the
Ionis calls for applications for Janice Wiesman Young Investigator Grant Program
– $50,000 grant will fund research and understanding of transthyretin amyloidosis CARLSBAD, Calif. , March 7, 2022 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced it is now accepting applications for the Janice Wiesman Young Investigator Grant Program , which honors
Ionis to present at the Cowen Annual Health Care Conference
CARLSBAD, Calif. , March 1, 2022 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in a panel discussion on orphan neurological disease therapeutics at the virtual Cowen 42 nd Annual Health Care Conference at 9:10 a.m.